DNA Vaccines Expressing the Envelope and Membrane Proteins Provide Partial Protection Against SARS-CoV-2 in Mice.
Front Immunol
; 13: 827605, 2022.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1742217
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a public health emergency of international concern, and an effective vaccine is urgently needed to control the pandemic. Envelope (E) and membrane (M) proteins are highly conserved structural proteins among SARS-CoV-2 and SARS-CoV and have been proposed as potential targets for the development of cross-protective vaccines. Here, synthetic DNA vaccines encoding SARS-CoV-2 E/M proteins (called p-SARS-CoV-2-E/M) were developed, and mice were immunised with three doses via intramuscular injection and electroporation. Significant cellular immune responses were elicited, whereas no robust humoral immunity was detected. In addition, novel H-2d-restricted T-cell epitopes were identified. Notably, although no drop in lung tissue virus titre was detected in DNA-vaccinated mice post-challenge with SARS-CoV-2, immunisation with either p-SARS-CoV-2-E or p-SARS-CoV-2-M provided minor protection and co-immunisation with p-SARS-CoV-2-E+M increased protection. Therefore, E/M proteins should be considered as vaccine candidates as they may be valuable in the optimisation of vaccination strategies against COVID-19.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Linfocitos T
/
Vacunas contra la COVID-19
/
Proteínas M de Coronavirus
/
Proteínas de la Envoltura de Coronavirus
/
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Ensayo controlado aleatorizado
Tópicos:
Vacunas
Límite:
Animales
/
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Front Immunol
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
Fimmu.2022.827605
Similares
MEDLINE
...
LILACS
LIS